TSO3 Receives Health Canada clearance for STERIZONE(R) 125L+ Sterilizer

    
    Stock symbol: TSX: TOS
    Outstanding shares: 47,863,402
    

QUÉBEC CITY, Dec. 17 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator of low temperature sterilization technology using ozone for medical devices in healthcare settings, today announced that Health Canada has approved the STERIZONE(R) 125L+ Sterilizer for sale in Canada.

The STERIZONE(R) 125L+ Sterilizer offers three new cycles in a single sterilizer and meets healthcare demands for speed and compatibility that previously required two or more sterilization systems. The device will be available through 3M Canada's distribution in 2010.

"This market clearance in Canada is perfectly timed with our recently announced distribution agreement with 3M, a global leader in infection prevention," stated R.M. (Ric) Rumble, CEO, TSO3. "The partnership with 3M adds credibility and channel strength, and we are working with 3M Canada to capitalize on the opportunity."

TSO3's new low temperature sterilization system offers speed, high throughput, increased instrument compatibility, and cost effective sterilization, and is engineered to be safe and eco-friendly. The new cycles accommodate general surgical instruments, and short and long, rigid or flexible endoscopes including complex multi-channel devices.

"Hospitals are actively looking for a complete low temperature solution and the STERIZONE(R) 125L+ Sterilizer meets those requirements," said Melanie Rice, Marmketing Supervisor, Infection Prevention Solutions, 3M Canada. "Based on calls received after announcing yesterday's distribution agreement, 3M Canada looks forward to expanding its product offering with TSO3's new sterilizer to better meet customer needs", concluded Ms Rice.

For more information about TSO3 and the STERIZONE(R) 125L+ Sterilizer, visit www.tso3.com.

About 3M Canada

Established in 1951, 3M Canada Company was one of the first international subsidiaries opened by 3M and remains one of the largest. 3M Canada's head office and original manufacturing site is in London, Ontario where approximately half of the company's 1,800 employees work. Other Ontario plants are located in Ottawa, Toronto, Brockville, and Perth with one in Morden, Manitoba. Sales offices are located in major cities nationwide and a national service network supports customers.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

In contrast to other methods, the ozone sterilization process developed and patented by TSO3 combines attributes that answer market needs for: efficacy, costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.

The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by the US and Canadian regulatory agencies for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearance from Health Canada and the US Food and Drug Administrations for sterilization of additional complex medical devices, including multi-channel flexible endoscopes.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE TSO3 Inc.

For further information: For further information: Caroline Côté, Director, Corporate Communications and IR, TSO3 Inc., (418) 651-0003, Ext. 237, ccote@tso3.com; Jacqui Newell, Public Relations Coordinator, 3M Canada, (519) 451-2500, Ext. 2564, jnewell@mmm.com; Source: TSO3 Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890